

# BIJOY HANS LIMITED

CIN: L51909AS1985PLC002323

**Date: 30.07.2025**

**To,**  
**Corporate Relations Department**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400 001

**Scrip Code: 524723**  
**Script ID: BIJHANS**

Sub: Newspaper Advertisements of the Un-audited Financial Results for the quarter ended on June 30, 2025.

Dear Sir/Madam,

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Newspaper cuttings of the Un-audited Financial Results of the Company for the first quarter ended June 30, 2025, as approved by the Board of Directors in their Meeting held on July 28, 2025, and published in “Financial Express Newspaper (English Edition) and Dainandin Barta” (Guwahati edition) on July 29, 2025.

The advertisement also includes a Quick Response code and the web link to access complete financial results for the said period. The above information is being uploaded on the website of the Company at [www.bijoyhans.net](http://www.bijoyhans.net).

Submitted for your kind information and necessary records.

**Thanking you,**  
**For Bijoy Hans Limited**

**GUINEA** Digitally signed by  
GUINEA AGRAWAL  
**AGRAWAL** Date: 2025.07.30  
12:31:23 +05'30'

**Company Secretary and Compliance Officer**

Encl : : As above

### INDO TECH TRANSFORMERS LIMITED

CIN: L29113TN1992PLC022011  
 Regd. Office : Survey No. 153-210, Iluppapattu Village, Near Rajakulam, Kancheepuram (Dist.) Tamilnadu - 631561. Tel: +91 44 27281854  
 Email: investor@indo-tech.com; Website: www.indo-tech.com

#### SPECIAL WINDOW FOR RE-LODGE-MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES

In accordance with SEBI Circular no. SEBI/HO/MIRSD/MIRSD-PoD/PI/CIR/2025/97 dated July 2, 2025, shareholders of the company are hereby informed that a special window has been opened from July 7, 2025 to January 06, 2026, for re-lodgement of transfer deeds.

Shareholders are to note that this window is only for re-lodgement of transfer deeds, which were lodged prior to the deadline of April 01, 2019 for transfer of physical shares, and rejected/ returned/ not attended to due to deficiency in the documents/ process/ or otherwise.

Shareholders who wish to avail the opportunity are requested to contact our Registrar and Share Transfer Agent, MUFG Intime India Private Limited (Formerly Link Intime India Private Limited), contact number: 022-49186000 / 49186175; Mail ID: mt.helpdesk@linkintime.co.in.

For INDO-TECH TRANSFORMERS LIMITED  
 Shiva Prasad Padhy  
 Company Secretary

### TAMIL NADU MAGNESITE LTD

(A GOVT OF TAMIL NADU UNDERTAKING)  
 5/53, OMALUR MAIN ROAD, JAGR AMMAPALAYAM POST, SALEM - 636 302, TAMIL NADU  
 Website: www.tanmag.in  
 e-mail: tanmag.salem@gmail.com  
 Mobile: 94427 00734

#### NOTICE INVITING e-TENDER

01	Description	PRODUCTION & TRANSPORTATION OF RAW MAGNESITE AND DUNITE FOR TWO YEARS PERIOD.
02	Tender No & Date	3/ADVT/CONTRACT/2025-26 & 28.07.2025
03	Tender ID	2025_TNMMAG_585712_1
04	EMD amount	Rs.35,80,200/-
04	Bid submission end date	28.08.2025 14.00 hrs
05	Technical bid opening date	29.08.2025 14.00 hrs

Note : For further details please visit Tamil Nadu e-tendering portal: <https://tenders.gov.in>, [www.tanmag.in](http://www.tanmag.in)  
 DIPR/ 3859 /TENDER/2025

Manager (Mines)

### OSWAL MINERALS LIMITED

Regd. Off: 8/11, Police Station Road, Pallavaram, Chennai - 600 043  
 Corporate Office: 'Oswal's', 1034, 2nd Floor, Dr. Rajkumar Road, 4th Block, Rajajinagar, Bangalore 560010. CIN: L30066TN1998PLC035973. Email: info@oswalminerals.com

#### NOTICE

##### SPECIAL WINDOW FOR RE-LODGE-MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES

Notice is hereby given in terms of SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/PI/CIR/2025/97 dated 2 July 2025, a Special Window has been opened for re-lodgement of transfer deeds, which were lodged prior to the deadline of 1 April, 2019 and rejected/returned/not attended due to deficiency in the documents/process or otherwise. The re-lodgement window shall remain open for a period of six months i.e. from 7 July 2025 till 6 January 2026.

During this period, the securities that are re-logged for transfer (including those requests that are pending with the Company/RTA, as on date) shall be issued only in demat mode. Due process shall be followed for such transfer-cum-demat requests.

Shareholders who have missed the earlier deadline of 31st March, 2021 are encouraged to take advantage of this opportunity by furnishing the necessary documents to the Company's Registrar and Share Transfer Agents (RTA), i.e. Ms. Camo Corporate Service Ltd., Subramanian Building, 1, Club House Rd, near Spencer's Signal on Anna Salai, Royapettah, Chennai, Tamil Nadu 600002. E-mail: camo@camoindia.com or the Company at E-mail: info@oswalminerals.com for further assistance.

For M/s. Oswal Minerals Limited  
 Sd/-  
 Milan Maroti  
 Company Secretary

Place: Bengaluru  
 Date: 29.07.2025

### CONTAINER CORPORATION OF INDIA LTD.

भारतीय कंटेनर निगम लिमिटेड  
 (A MAURITIUS UNDER TAKING OF GOVT. OF INDIA)  
 (A COMPANY INCORPORATED IN MAURITIUS)

#### NOTICE INVITING E-TENDER

CONCOR invites E-Tender in Two Packet System of tendering for the following work:-

Tender No.	CON/Area-III/ENG/VIZAG/E-87909/2025-26
Name of Work	Construction of sick-line shed for ROH facility and allied works at MMLP Vizag
Estimated Cost	Rs.1066.77 Lakhs (including GST)
Completion Period	12 (Twelve) Months
Earnest Money Deposit	Rs.63,400.00 (Rupees Six Lakhs Fifty Three Thousand Four Hundred only)
Cost of Tender Document (Non-refundable)	Nil
Tender Processing Fee (Non-refundable)	Rs.3,540/- (inclusive all taxes & duties through e-payment)
Date of sale of Tender (online)	29.07.2025 (from 15:00 hrs.) to 18.08.2025 (upto 17:00 hrs.)
Date & Time of submission of Tender	19.08.2025 up to 17:00 hrs.
Date & Time of Opening of Tender	21.08.2025 at 11:00 hrs.

For financial eligibility criteria, experience with respect to similar nature of work, etc, please refer to detailed tender notes available on website [www.concorindia.co.in](http://www.concorindia.co.in) but the complete tender document can be downloaded from website [www.tenderward.com/CCL](http://www.tenderward.com/CCL) only. Further, Comgenium/Addendum to this Tender, if any will be published on website [www.concorindia.co.in](http://www.concorindia.co.in), [www.tenderward.com/CCL](http://www.tenderward.com/CCL) and Central Procurement Portal (CPP) only. Newspaper press advertisement shall not be issued for the same.

Executive Director (Projects) Phone No.-011-41222500

### NATIONAL FITTINGS LIMITED

S.F.No. 112, Madhapur Road, Kaniyur, Karumathampatti Via, Sulur Taluk, Coimbatore - 641 659.  
 Email ID : [accounts@nationalfitting.com](mailto:accounts@nationalfitting.com), Website : [www.nationalfitting.com](http://www.nationalfitting.com)  
 Ph : 9943293000 / 9943993001

#### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE 2025

CIN : L291997Z1993PLC008034 (Rs. in Lakhs except share data)

Particulars	Unaudited		Audited
	Quarter ended		Year ended
	30.06.2025	30.06.2024	31.03.2025
Total income from operations (net)	2058.19	1514.38	7813.33
Net Profit / (Loss) from ordinary activities before tax *	359.75	41.90	701.93
Net Profit / (Loss) from ordinary activities after tax *	262.25	692.82	2330.34
Total Comprehensive Income for the period	-	-	31.34
Net Profit after other Comprehensive Income	262.25	692.82	2299.00
Equity Share Capital	908.32	908.32	908.32
Other Equity (excluding Revaluation Reserve)	7451.51	5719.32	7189.25
Earnings Per Share (of ₹ 10/- each) Basic and Diluted	2.89	7.63	25.66

\* The Company does not have any extraordinary item to report for the above periods.

Notes :  
 1. The above result has been reviewed by Audit Committee and approved by the Board of Directors at their respective meetings held on 28th July 2025.  
 2. The above is an extract of the detailed format of Unaudited Financial Results for the Quarter ended 30th June 2025 filed with Stock Exchange under regulation 33 of the SEBI (Listing and other disclosure requirements) Regulations, 2015. The Full format of the Quarter ended Financial Results are available on the Stock Exchange websites : [www.bseindia.com](http://www.bseindia.com) and on Company's website at [www.nationalfitting.com](http://www.nationalfitting.com).

For National Fittings Limited  
 Sd/- Jayaram Govindarajan  
 Managing Director  
 DIN:02178416

Place : Coimbatore  
 Date : 28.07.2025

### NEPHROPLUS NEPHRO CARE HEALTH SERVICES LIMITED

OUR COMPANY IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES NOR IT IS A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.

INITIAL PUBLIC OFFERING OF EQUITY SHARES OF THE COMPANY ON THE MAIN BOARD OF THE BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS")

#### PUBLIC ANNOUNCEMENT

Our Company was incorporated as "Nephrocare Health Services Private Limited", a private limited company under the Companies Act, 1956, at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh ("RoC Andhra Pradesh") on December 18, 2009. Pursuant to resolutions dated April 11, 2025 and June 2, 2025 passed by our Board and Shareholders, respectively, our Company was converted into a public limited company and consequently, the name of our Company was changed to "Nephrocare Health Services Limited" with a fresh certificate of incorporation dated June 18, 2025 issued by the Registrar of Companies, Central Registration Centre. See "History and Certain Corporate Matters - Changes in the Registered Office" on page 316 of the draft red herring prospectus dated July 25, 2025 ("DRHP").

Registered and Corporate Office: 5<sup>th</sup> Floor, D Block, ilabs Centre, Plot 18, Software Units Layout, Survey No. 64, Madhapur, Shaikpet, Hyderabad 500 081, Telangana, India  
 Contact Person: Kishore Kathri, Company Secretary and Compliance Officer; Tel: +91 400 8039, E-mail: [cs@nephroplus.com](mailto:cs@nephroplus.com); Website: [www.nephroplus.com](http://www.nephroplus.com);  
 Corporate Identity Number: U85100TG2009PLC066359

#### PROMOTERS OF OUR COMPANY: VIKRAM VUPPALA, BESSEMER VENTURE PARTNERS TRUST, EDORAS INVESTMENT HOLDINGS PTE. LTD., HEALTHCARE PARENT LIMITED, INVESTCORP PRIVATE EQUITY FUND II AND INVESTCORP GROWTH OPPORTUNITY FUND

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF NEPHRO CARE HEALTH SERVICES LIMITED ("OUR COMPANY" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE FACE VALUE OF ₹2 (INCLUDING A SECURITIES PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION ("OFFER") COMPRISING A FRESH ISSUE OF [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹534.05 MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 12,792,056 EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("OFFERED SHARES") AGGREGATING UP TO ₹[●] MILLION, COMPRISING AN OFFER FOR SALE OF UP TO 1,660,360 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY INVESTCORP PRIVATE EQUITY FUND II AND UP TO 1,813,140 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY HEALTHCARE PARENT LIMITED AND UP TO 147,765 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY INVESTCORP GROWTH OPPORTUNITY FUND AND UP TO 4,081,000 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY EDORAS INVESTMENT HOLDINGS PTE. LTD. ("PROMOTER SELLING SHAREHOLDERS") AND UP TO 121,985 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY INVESTCORP INDIA PRIVATE EQUITY OPPORTUNITY LIMITED AND UP TO 3,089,663 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY INTERNATIONAL FINANCE CORPORATION AND UP TO 1,433,468 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY 360 ONE SPECIAL OPPORTUNITIES FUND - SERIES 9 AND UP TO 444,675 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY 360 ONE SPECIAL OPPORTUNITIES FUND - SERIES 10 ("OTHER SELLING SHAREHOLDERS") AND TOGETHER WITH THE PROMOTER SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS" AND SUCH OFFER FOR SALE BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", THE OFFER SHALL CONSTITUTE [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH, AGGREGATING UP TO ₹[●] MILLION (CONSTITUTING UP TO [●]%) OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL, FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES ("EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HERINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER SHALL CONSTITUTE [●] AND [●] OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY, RESPECTIVELY. OUR COMPANY, MAY IN CONSULTATION WITH THE BRLMS, OFFER A DISCOUNT OF [●] ON THE ISSUE PRICE TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT").

THE FACE VALUE OF THE EQUITY SHARES IS ₹2 EACH. THE OFFER PRICE IS [●] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, AND WILL BE ADVERTISED IN ALL EDITIONS OF [●] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), ALL EDITIONS OF [●] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND [●] (A WIDELY CIRCULATED TELUGU DAILY NEWSPAPER, TELUGU BEING THE REGIONAL LANGUAGE OF TELANGANA, WHERE OUR REGISTERED OFFICE IS LOCATED) AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS AND SUCH ADVERTISEMENT SHALL BE MADE AVAILABLE TO BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR UPLOADING ON THEIR RESPECTIVE WEBSITES.

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A FURTHER ISSUE OF SPECIFIED SECURITIES (I.E., FULLY PAID-UP PREFERENCE SHARES AND/OR EQUITY SHARES) TO CERTAIN INVESTORS FOR AN AMOUNT AGGREGATING UP TO ₹706.81 MILLION ("PRE-IPO PLACEMENT"), AS PERMITTED UNDER APPLICABLE LAWS ON OR PRIOR TO THE DATE OF FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SCRR. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND PROSPECTUS.

In case of any revision in the Price Band, the Bid/ Offer Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of one Working Day, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice and also by indicating the change on the websites of the BRLMs and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank(s), as applicable.

The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR"), read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to QIBs (the "QIB Portion"), provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors and the basis of such allocation will be on a discretionary basis by our Company, in consultation with the BRLMs, in accordance with the SEBI ICDR Regulations (the "Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("Anchor Investor Allocation Portion"). In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the remaining QIB Portion (other than Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. Further, not less than 15% of the Net Offer shall be available for allocation to NII's ("Non-Institutional Category") of which one-third of the Non-Institutional Category shall be available for allocation to Bidders with an application size of more than ₹1,000,000 and under-subscription in either of these two sub-categories of Non-Institutional Category may be allocated to Bidders in the other sub-category of Non-Institutional Category in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not less than 35% of the Net Offer shall be available for allocation to RILs ("Retail Category"), in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders, other than the Anchor Investors, shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process, providing details of their respective bank accounts (including UPI ID (defined hereinafter) for UPI Bidders (defined hereinafter) in which the Bid amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or the Sponsor Bank(s) under the UPI Mechanism, as the case may be, to the extent of the respective Bid Amounts. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. For further details, see "Offer Procedure" beginning on page 523 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP dated July 25, 2025 with the SEBI and with the Stock Exchanges on July 26, 2025. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and Stock Exchanges shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of publication of this public announcement, by hosting it on the website of [www.sebi.gov.in](http://www.sebi.gov.in), websites of the Stock Exchanges i.e., BSE at [www.bseindia.com](http://www.bseindia.com) and NSE at [www.nseindia.com](http://www.nseindia.com), respectively, on the website of the Company at [www.nephroplus.com](http://www.nephroplus.com) and the websites of the BRLMs, i.e., ICFI Securities Limited, Ambit Private Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited) and Nomura Financial Advisory and Securities (India) Private Limited at [www.icfisecurities.com](http://www.icfisecurities.com), [www.ambit.co](http://www.ambit.co), [www.iiflcap.com](http://www.iiflcap.com) and [www.nomuraholdings.com/company/group/asia/india/index.html](http://www.nomuraholdings.com/company/group/asia/india/index.html), respectively. Our Company hereby invites the public to provide comments on the DRHP filed with SEBI and the Stock Exchanges with respect to disclosures made therein. The public are requested to send a copy of the comments to either, SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs and the Registrar to the Issue at their respective addresses mentioned below. All comments must be received by our Company and/or the BRLMs and/or the Registrar to the Issuer and/or the Company Secretary and Compliance Officer of our Company on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares of face value of ₹2 each have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 43 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be made after the Red Herring Prospectus ("RHP") and must be made solely on the basis of such RHP that shall be filed with the RoC as there may be material changes in the RHP from the DRHP.

The Equity Shares, when offered, through the RHP, are proposed to be listed on BSE and NSE. For details of the main objects of the Company as contained in its Memorandum of Association, see "History and Certain Corporate Matters" on page 316 of the DRHP. The liability of the members of the Company is limited by shares. For details of the share capital and capital structure of the Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of the Company see "Capital Structure" on page 114 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE ISSUE
<b>ICICI Securities Limited</b> ICICI Venture House Appasaheb Marathe Marg, Prabhadevi Mumbai 400 025 Maharashtra, India Tel: +91 22 6807 7100 E-mail: <a href="mailto:nephroplus ipo@icfisecurities.com">nephroplus ipo@icfisecurities.com</a> Website: <a href="http://www.icfisecurities.com">www.icfisecurities.com</a> Contact Person: Aboli Pitre / Namrata Ravasia Investor Grievance ID: <a href="mailto:customer-care@icfisecurities.com">customer-care@icfisecurities.com</a> SEBI Registration No.: INM000011179	<b>Ambit Private Limited</b> Ambit House, 449 Senapati Bapat Marg Lower Parel Mumbai 400 013 Maharashtra, India Tel: +91 22 6623 9030 E-mail: <a href="mailto:nephroplus ipo@ambit.co">nephroplus ipo@ambit.co</a> Website: <a href="http://www.ambit.co">www.ambit.co</a> Contact Person: Siddhesh Deshmukh/ Anuradhati Iyer Investor grievance e-mail: <a href="mailto:customerservice@ambit.co">customerservice@ambit.co</a> SEBI Registration No.: INM000010585	<b>IIFL Capital Services Limited</b> (formerly known as IIFL Securities Limited) 24 <sup>th</sup> Floor, One Lodha Place Senapati Bapat Marg, Lower Parel (West), Mumbai 400 013 Maharashtra, India Tel: +91 22 4646 4728 E-mail: <a href="mailto:nephroplus ipo@iiflcap.com">nephroplus ipo@iiflcap.com</a> Website: <a href="http://www.iiflcap.com">www.iiflcap.com</a> Contact Person: Yogesh Malpani / Pawan Kumar Jain Investor grievance e-mail: <a href="mailto:ig_ib@iiflcap.com">ig_ib@iiflcap.com</a> SEBI Registration No.: INM000010940	<b>Nomura Financial Advisory and Securities (India) Private Limited</b> Ceejay House, Level 11 Plot F, Shivsagar Estate Dr. Annie Besant Road, Worli Mumbai 400 018, Maharashtra, India Tel: +91 22 4037 4037 E-mail: <a href="mailto:nephroplus ipo@nomura.com">nephroplus ipo@nomura.com</a> Website: <a href="http://www.nomuraholdings.com/company/group/asia/india/index.html">www.nomuraholdings.com/company/group/asia/india/index.html</a> Contact Person: Vishal Kanjani / Chirag Shah Investor grievance e-mail: <a href="mailto:investorgrievances-in@nomura.com">investorgrievances-in@nomura.com</a> SEBI Registration No.: INM000011419	<b>KFin Technologies Limited</b> Selenium, Tower B, Plot No - 31 and 32, Financial District, Nanakramguda Serilingampally, Hyderabad 500 032, Telangana, India Tel: +91 40 6716 2222 E-mail: <a href="mailto:nephrocare ipo@kfintech.com">nephrocare ipo@kfintech.com</a> Website: <a href="http://www.kfintech.com">www.kfintech.com</a> Contact Person: M Murali Krishna Investor grievance e-mail: <a href="mailto:eiward.ns@kfintech.com">eiward.ns@kfintech.com</a> SEBI Registration Number: INR000000221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

Place: Hyderabad, Telangana  
 Date: July 28, 2025

For NEPHRO CARE HEALTH SERVICES LIMITED  
 On behalf of the Board of Directors  
 Sd/-  
 Kishore Kathri  
 Company Secretary and Compliance Officer

NEPHRO CARE HEALTH SERVICES LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 26, 2025. The DRHP shall be available on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), and is available on the website of the Stock Exchanges i.e. BSE and NSE at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com), respectively, on the website of the Company at [www.nephroplus.com](http://www.nephroplus.com) and the websites of the BRLMs, i.e., ICFI Securities Limited, Ambit Private Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited) and Nomura Financial Advisory and Securities (India) Private Limited at [www.icfisecurities.com](http://www.icfisecurities.com), [www.ambit.co](http://www.ambit.co), [www.iiflcap.com](http://www.iiflcap.com) and [www.nomuraholdings.com/company/group/asia/india/index.html](http://www.nomuraholdings.com/company/group/asia/india/index.html), respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" beginning on page 43 of the DRHP. Potential investors should not rely on the DRHP filed with SEBI and the Stock Exchanges, and should instead rely on their own examination of our Company and the Offer, including the risks involved, for making any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

### BIJOY HANS LIMITED

(CIN: L51909AS1985PLC002323)  
 Registered Office: H.P. Brahmachari Road, Rehabar, Kamrup, Guwahati, Assam, India. 781008;  
 Corporate Office: Unit No 408 Third floor Royal Miraj Arcade, Laxmi Market Miraj Shrikant Chowk Miraj, Miraj, Sangli, Miraj, Maharashtra, India. 416410  
 Tel No: +91 7066670199, E-mail ID: [compliance@arvayhealth.com](mailto:compliance@arvayhealth.com), Website: [www.bijoyhans.net](http://www.bijoyhans.net)

#### Extract of Standalone Unaudited financial result for the quarter ended 30<sup>th</sup> June, 2025

(Rs. in Lakhs)

S. No	Particulars	Quarter ended 30-06-2025 (Unaudited)	Quarter ended 30-06-2024 (Unaudited)	Year Ended 31-03-2025 (Audited)
1.	Total income from operations	3.41	14.36	46.87
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(25.29)	(5.25)	(36.77)
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(25.29)	(5.25)	19.09
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(25.29)	(5.25)	13.62
5.	Total Comprehensive Income for the period (Comprising profit/loss) for the period(after tax) and other Comprehensive Income(after tax)	(25.29)	(5.25)	13.62
6.	Equity Share Capital (of Rs. 10/- each)	700	300	300
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	0.00	0.00	0.00
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)- Basic : Diluted :	(0.53) (0.53)	0.00 0.00	0.45 0.45

Notes:  
 1. The Statement of unaudited Financial Result for the Quarter ended 30th June, 2025 have been reviewed by the Audit Committee and have been approved and taken on record by the Board of Directors at their meeting held on 28th July 2025.  
 2. These Financial results have been prepared in accordance with the Indian Accounting Standard (Ind-AS) prescribed under Section 133 of the Company Act, 2013, read with relevant rules issued thereunder.  
 3. The Company has only one reportable business segment. Hence, separate information for segment wise disclosure is given in accordance with the requirements of Ind AS (AS) 108 - "Segment Reporting" is not required.  
 4. The company has issued and allotted 45,00,000 number of Equity shares through preferential allotment to new promoters, at issue price of Rs. 12.50 per share. This allotment was carried out in accordance with Section 62(1)(c) of the Companies Act, 2013 and Rule 13 of the Companies (Share Capital & Debentures) Rules, 2014.  
 5. The above is an extract of detailed format of quarterly financial result filed with Stock Exchange under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of quarterly financial results are available on the Stock Exchange website [www.bseindia.com](http://www.bseindia.com) and Company's website [www.bijoyhans.net](http://www.bijoyhans.net).

For and on behalf of the Board  
 For Bijoy Hans Limited  
 Sd/-  
 Guineas Agrawal  
 Company Secretary and Compliance Officer  
 Membership: A60654

Place: Pune  
 Date: 28/07/2025

### helios MUTUAL FUND

Helios Mutual Fund  
 Helios Mutual Fund

#### NOTICE NO. 26/2025

Notice is hereby given that in accordance with Regulation 56 of Securities and Exchange Board of India (Mutual Funds) Regulations, 1996 and circulars issued from time to time, the Scheme wise Annual report and abridged summary thereof of Helios Mutual Fund ("the Fund") for the year ended March 31, 2025 shall be hosted on the website of the Helios Mutual Fund viz. <https://www.heliosmf.in/downloads/and> on the website of AMFI viz. [www.amfiindia.com](http://www.amfiindia.com)

The scheme wise annual report or abridged summary thereof shall be emailed to those investors, whose email addresses are registered with the Mutual Fund. Investors can request for a physical copy or electronic copy of the scheme wise annual report or abridged summary thereof through any of the following modes :

- Telephone : Call at our Investor Contact Centre at 1800 2100 168 (toll free number)
- Email : Send an email to [customer-care@helioscapital.in](mailto:customer-care@helioscapital.in)
- Written Request (letter) to :
  - Registered office or any of the Investor Service Centres of Helios Capital Asset Management (India) Private Limited; or
  - Computer Age Management Services Ltd (CAMS) at New No.10, (Old No. 178), M.G.R. Salai, Nungambakkam, Chennai - 600 034.

Unitholders are requested to update their latest e-mail id and mobile number to help us serve better.

**For Helios Capital Asset Management (India) Private Limited**  
 (Investment Manager to Helios Mutual Fund)

Sd/-  
**Authorised Signatory**  
 Date : July 28, 2025  
 Place : Mumbai

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

**Helios Capital Asset Management (India) Private Limited**  
 (Formerly Helios Capital Management (India) Private Limited)  
 Registered Office : 515 A, 5<sup>th</sup> Floor, The Capital, Plot C70, Bandra Kurla Complex, Bandra East, Mumbai - 400051, Maharashtra.  
 Corporate Office : 502, B Wing, The Capital, Plot C70, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.  
 Contact : 022-67319600, Website : [www.heliosmf.in](http://www.heliosmf.in)  
 Corporate Identification Number (CIN) : U67190MH2012PTC360838

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares of face value of ₹2 each have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 43 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be made after the Red Herring Prospectus ("RHP") and must be made solely on the basis of such RHP that shall be filed with the RoC as there may be material changes in the RHP from the DRHP.

The Equity Shares, when offered, through the RHP, are proposed to be listed on BSE and NSE. For details of the main objects of the Company as contained in its Memorandum of Association, see "History and Certain Corporate Matters" on

